Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.44 |
| ▸ | ACP1 | P24666 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.40 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.38 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | FLT4 | P35916 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20720655 | 0.85 | FLT3 (0.42) | AVPR1BKDR | |
| SCHEMBL20720718 | 0.85 | CACNA2D1 (0.46) | CACNA2D1ACP1L3MBTL1HRH3KCNH2 | |
| SCHEMBL20720751 | 0.85 | CACNA2D1 (0.46) | CACNA2D1ACP1L3MBTL1HRH3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL20720656 | 0.82 | CACNA2D1 (0.50) | CACNA2D1ACP1L3MBTL1HRH3KCNH2 | |
| SCHEMBL20720729 | 0.79 | EHMT2 (0.52) | ADRA1AEHMT2EHMT1 | |
| SCHEMBL20720716 | 0.79 | EHMT2 (0.50) | EHMT2EHMT1 | |
| SCHEMBL20720682 | 0.78 | EHMT2 (0.43) | HTR4EHMT2 | |
| SCHEMBL20720626 | 0.77 | ACP1 (0.46) | CACNA2D1ACP1HRH3KCNH2ADRA1A | |
| SCHEMBL19260586 | 0.76 | CACNA2D1 (0.58) | CACNA2D1ACP1L3MBTL1HRH3KCNH2 | |
| SCHEMBL20720618 | 0.75 | EHMT2 (0.38) | HTR4AVPR1BEHMT2EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254651-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3416963-B1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | CACNA2D1 1539/4885ACP1 3686/4885L3MBTL1 72/4885 |
| US-11254651-B2 | Histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | CACNA2D1 1539/4885ACP1 3686/4885L3MBTL1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.